Alerta

NANOPARTICLES AND USES THEREOF

Resumen de: AU2025234040A1

The present disclosure relates generally to nanoparticles and compositions comprising the same, and their use for transfecting transfection-recalcitrant cells, wherein the nanoparticle is tethered to an antigen-binding moiety having binding specificity for an antigen expressed on the surface of the cell, such as cluster of differentiation 2 (CD2) or cluster of differentiation 7 (CD7), wherein the nanoparticle comprises at least an ionisable lipid and a sterol.

Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof

Resumen de: AU2026238128A1

Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle. ep e p

Formulations

Resumen de: AU2026242118A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/067992 A1 04 April 2019 (04.04.2019) WIPO|PCT (51) International Patent Classification: Published: C12N 15/113 (2010.01) A61K 9/127 (2006.01) with international search report (Art. 21(3)) C12N 15/88 (2006.01) A61K 31/7088 (2006.01) before the expiration of the time limit for amending the C12N 9/22 (2006.01) claims and to be republished in the event of receipt of (21) International Application Number: amendments (Rule 48.2(h)) PCT/US2018/053559 (22) International Filing Date: 28 September 2018 (28.09.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/566,240 29 September 2017 (29.09.2017) US (71) Applicant: INTELLIA THERAPEUTICS, INC. US/US; 40 Erie Street, Cambridge, MA 02139 (US). (72) Inventors: WOOD, Kristy, M.; 34 Earle Road, Welles- ley, MA 02481 (US). GARDNER, Noah, Paul; 41 Mc- Clellan Road, Sutton, MA 01590 (US). SHAH, Ruchi, Rudraprasad; 90 Riverpath Drive, Apartment 19, Fram- ingham, MA 01701 (US). SCULLY, Stephen, S.; 91 Slade Street, Belmont, MA 02478 (US). MAJZOUB, Ramsey; 1 Longfellow Place, #716, Boston, MA 02114 (US). (74) Agent: BENCIVENGA, Nicholas, E.; Finnegan, Hender- son, Farabow, Garrett & Dunner, LLP, 901 New York Av- enue, NW, Washington, DC 20001 (US). (81) Designated States (unle

IONISABLE LIPIDS

Resumen de: AU2026238051A1

The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided. ep e p

METHODS OF SYNTHESIZING AMINE LIPIDS

Resumen de: AU2025251559A1

Described herein are methods of synthesizing ionizable amine lipids, such as Lipid A: with increased overall purity, process robustness and an applied impurity control strategy, leading to a substantially pure Lipid A product. Intermediate compounds and methods of synthesizing intermediate compounds are also described.

SMALL ZWITTERIONIC MULTIMERIC TARGETED DRUGS AND METHODS OF USE AND MANUFACTURE THEREOF

Resumen de: AU2025374772A1

In accordance with at least one aspect of this disclosure, there is provided a small zwitterionic multimeric targeted anti-cancer drug which effectively addressed tumor cell heterogeneity and off-target/non-specific binding and uptake. The small zwitterionic multimeric targeted anti-cancer drug includes a nexus, three different targeting ligands conjugated to the nexus, a payload of a zwitterionic diagnostic or therapeutic agent, and zwitterionic flexible linkers connecting each of the three different targeting ligands and the pay load to the nexus.

LIPID NANOPARTICLE FORMULATION AND PREPARATION METHOD THEREFOR

Resumen de: AU2025254683A1

A lipid nanoparticle formulation having remarkably improved stability and a preparation method therefor. The lipid nanoparticle formulation comprises a pharmaceutically acceptable buffer solution, lipid nanoparticles and a nucleic acid encapsulated in the lipid nanoparticles.

COMPOSITIONS AND ASSOCIATED METHODS FOR CHITOSAN-BASED NANO-CARRIERS FOR THERAPEUTIC AGENTS AND THEIR APPLICATIONS

Resumen de: AU2025248899A1

Provided herein are compositions and associated methods for CH-based nano-carriers for therapeutic agents and their applications, a multi-step method for the synthesis of the pharmacologically stable and multifunctional CH-based nano-carriers, effectively carrying therapeutic or theranostic radioactive metal isotope, anionic immunotherapeutic agent, or other anionic therapeutic agents used as therapeutic drugs, including the one of "combined radio-and adjuvant immuno-therapy" for cancer treatment.

LIPID NANOPARTICLES FOR STIMULATING T CELLS

Resumen de: AU2025252440A1

The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating CD8+ T cells associated with protein or protein fragments of interest. The lipid nanoparticles can have a negative zeta potential and/or particular configurations and/or relative amounts of a phospholipid, an ionizable lipid, and a conjugated lipid. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.

IONISABLE LIPIDS

Resumen de: AU2026238052A1

The present disclosure relates to ionisable lipids of Formula I and related structures that comprise a headgroup, core, and hydrophobic substituents. The lipids are capable of forming lipid particles, including lipid nanoparticles (LNPs), in combination with additional lipids such as neutral lipids, charged lipids, structural lipids, or PEGylated lipids. The lipid particles are suitable for delivery of therapeutic agents, including polynucleotides, peptides, antibodies, and small molecules. Compositions comprising the ionisable lipids and methods of forming and using the lipid particles are also provided. ep e p

NANO-EMULSIONS AND FORMULATIONS THEREOF FOR DELIVERING ACTIVE INGREDIENTS

Resumen de: EP4821482A1

The present disclosure relates to compositions that include oily nanocores containing oligo/polynucleotides, e.g., in the form of nano-emulsions, for the prevention or treatment of diseases. In particular, it relates to an oil-in-water nano-emulsion composition comprising : (a) an ionizable cationic lipid, (b) a permanently cationic lipid, (c) an oil, (d) a surfactant, (e) an active ingredient comprising an oligonucleotide and/or a polynucleotide, (f) an aqueous medium, optionally comprising , at least one of (g) a PEG-lipid, (h) an amphiphilic polymer, and (i) a hydrophilic polymer, and, further optionally comprising, (j) an additional lipid selected from a phospholipid, a fatty acid, a fatty acid derivative, and a fatty amine, wherein the nano-emulsion composition comprises from 8.0 to 60.0 mol% of ionizable cationic lipid (a), from 8.0 to 40.0 mol% of permanently cationic lipid (b), and a molar ratio of (a) to (b) from 1:1 to 3:1, wherein the mol % is with respect to the total mols of (a), (b), (c), (d), and, if present, (g) and (j).The present disclosure further relates to said composition in lyophilized form, a reconstructed nano-emulsion from the lyophilized composition, formulations comprising said compositions and a pharmaceutically acceptable excipient, to methods for the preparation of said compositions, and to medical uses of said compositions and formulations for the treatment or prevention of a disease or disorder.

NOVEL SYMMETRICAL IONIZABLE LIPIDS BASED ON A GLYCEROL TRIESTER CORE AND ACETAL-BEARING SUBSTITUENTS AND THEIR USES IN LIPID NANOPARTICLES

Resumen de: EP4821494A1

Disclosed herein are ionizable lipids defined as compounds of Formula (I or pharmaceutically acceptable salts thereof. Also disclosed are lipid nanoparticles comprising a compound of Formula or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising a compound of Formula (I), as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a nucleic acid segment.

CHITOSAN-BASED NANOCAPSULE SYSTEM FOR USE IN THE PROPHYLACTIC TREATMENT OF AN INFECTION CAUSED BY A RESPIRATORY PATHOGEN

Resumen de: EP4821490A1

0001 The present invention refers to the medical field. Particularly, it refers to a chitosan-based nanocapsule system for use in the prophylactic treatment of an infection caused by a respiratory pathogen, preferably the influenza virus, wherein the nanocapsule system is administered intranasally.

NOVEL SYMMETRICAL IONIZABLE LIPIDS BASED ON A GLYCEROL TRIESTER CORE AND THEIR USES IN LIPID NANOPARTICLES

Resumen de: EP4821915A1

0001 Disclosed herein are ionizable lipids defined as compounds of Formula (I or pharmaceutically acceptable salts thereof. Also disclosed are lipid nanoparticles comprising a compound of Formula or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising a compound of Formula (I), as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a nucleic acid segment.

ANTI-MET/EGFR BISPECIFIC ANTIBODY AND DRUG CONJUGATE THEREOF

Resumen de: EP4821950A1

0001 Provided is an anti-MET nanobody and an anti-EGFR nanobody, and a bispecific antibody comprising the two nanobodies. Also provided is a drug conjugate constructed on the basis of the nanobodies and the bispecific nanobody.

IONIZABLE LIPIDS

Resumen de: WO2025134066A1

The present disclosure provides, among other things, a compound of formula I, I or a pharmaceutically acceptable salt thereof, where G1, M1, M2, L1, L2, L3, T1, T2, and X are as defined in classes and subclasses herein, both singly and in combination; and uses thereof.

METHOD OF PRODUCING LEUKOCYTES EXPRESSING ARTIFICIAL ANTIGEN RECEPTORS

Resumen de: WO2025120230A1

The present invention relates to a lipid nanoparticle (LNP) suitable for transfecting a leukocyte, which nanoparticle comprises an mRNA encoding for a transposase enzyme, and a DNA encoding for an antigen receptor.

METAPNEUMOVIRUS (MPV) VACCINE

Resumen de: EP4822025A1

The present invention relates to a metapneumovirus (MPV) vaccine, wherein the nucleic acid comprises a polynucleotide encoding a mutant of an MPV F protein, and the mutant comprises disulfide bond mutations relative to a wild-type MPV F protein.

NOVEL COMPOSITIONS AND USES

Resumen de: WO2025116748A1

The present disclosure is concerned with compositions comprising monodisperse assemblies of allene oxide synthase (AOS), and in particular compositions and assembles comprising AOS enzymes and polysorbate surfactants. Such compositions have improved enzymatic activity that are particularly useful for remediating biological conditions of oxidative stress.

HYDROPHOBIC DRUGS IN ORGANIC CORE HIGH DENSITY LIPOPROTEIN (HDL) NANOPARTICLES

Resumen de: EP4821491A1

Disclosed herein are high-density lipoprotein-like nanoparticles (HDL-NP) having a soft material core (e.g., a lipid-conjugated inorganic core) associated with hydrophobic therapeutic agents. In some embodiments, the HDL-NPs are targeted to scavenger receptor type B1 (SR-B1). In some embodiments, the hydrophobic therapeutic agents are chemotherapeutic agents. Also disclosed herein are methods for treating disorders such as cancer with the HDL-NPs.

一种花菁衍生物-白蛋白纳米制剂及其制备方法与应用

Resumen de: CN122894518A

本发明属于纳米医学与肿瘤治疗领域，涉及一种花菁衍生物‑白蛋白纳米制剂及其制备方法与应用。所述花菁衍生物‑白蛋白纳米制剂，包含花菁衍生物和白蛋白，所述花菁衍生物和白蛋白的质量比为1:30‑200；所述花菁衍生物为以下结构所示的化合物、药学上可接受的盐：本发明的花菁衍生物‑白蛋白纳米制剂能够协同下调CD47、IDO1与GDF‑15等免疫逃逸/免疫抑制相关关键分子，实现对多通路免疫抑制网络的综合解除，从而降低耐受与复发风险。

药物组合物

Resumen de: WO2018052053A1

The present invention pertains to a therapeutic agent for ophthalmic diseases which comprises a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in the form of nanoparticles tending to be retained in a posterior ocular tissue when systemically administered.

一种治疗鼻炎的干细胞外泌体滴鼻液、制备方法及应用

Resumen de: CN122894317A

本发明提供一种治疗鼻炎的干细胞外泌体滴鼻液、制备方法及应用，涉及生物医学工程与制药技术领域，其包括间充质干细胞、黏附型缓释凝胶基质、姜黄素纳米微囊分散液、脂质体、明胶和PBS缓冲液，通过黏附型缓释凝胶基质在鼻腔内形成物理屏障，显著延长了外泌体的局部驻留时间，使24小时累积释放率达到65%‑70%，大幅降低了给药频率。外泌体携带的miRNA‑146a特异性抑制Th2型免疫应答，姜黄素纳米微囊阻断NF‑κB炎症通路，两者在免疫调节层面实现协同增效，同时修复鼻黏膜屏障功能。

一种复合益生菌与药食同源原料复配组合物及其制备方法

Resumen de: CN122894454A

本发明公开一种复合益生菌与药食同源原料复配组合物及其制备方法。该复配组合物包括预驯化复合益生菌、炮制药食同源原料及后生元浓缩液。其制备方法包括：山药麸炒、茯苓发酵炮制、黄芪和甘草蜜炙得炮制药食同源原料；经酶解得酶解液；复合益生菌在酶解液中厌氧预驯化得驯化菌液；驯化菌液接种于新鲜酶解液中厌氧发酵，实时监测乳酸与乙酸摩尔比，达2.0至2.5时降温并通入微量氧气继续发酵，还原糖含量小于2%时终止；分离发酵上清和菌体，上清浓缩得后生元浓缩液，菌体干燥得驯化菌粉；将驯化菌粉、后生元浓缩液与炮制药食同源原料加工物分层包埋复配，得复配组合物。本发明可用于制备修复肠屏障功能的药物或保健食品。

阳离子铂前药脂质纳米颗粒及制备方法和应用、药物组合

Nº publicación: CN122894330A 13/10/2026

Solicitante:

苏州大学

Resumen de: CN122894330A

本申请涉及纳米生物医药与肿瘤治疗技术领域，具体涉及一种阳离子铂前药脂质纳米颗粒及制备方法和应用、药物组合。该阳离子铂前药脂质纳米颗粒包括阳离子四价铂前药以及脂肪链修饰的还原响应两亲性高分子。通过将传统二价铂药物转化为结构稳定的四价铂前药，能够有效提高铂类药物在生理环境中的稳定性，减少药物在血液循环过程中的非特异性活化和提前释放，提升抗肿瘤效果；同时，通过采用脂肪链修饰及还原响应的两亲性高分子对其进行封装，有效提高了疏水性铂前药的水分散性和体内稳定性，延长药物循环时间，降低正常组织暴露，从而减轻传统铂类药物引起的肾毒性、神经毒性及骨髓抑制等非特异性毒副作用，提高药物治疗安全性。